Introduction
Pneumococcus is one of the major pathogens that leads communities to acquire respiratory infections such as pneumonia. In primary health-care institutions, the accurate diagnosis and rational use of antibiotics for the treatment of pneumocococcal infections is essential, not only for the patient ‘ s efficacy and prognosis, but also for the prevention of antibiotics abuse and drug-resistant bacteria. Archicin, as a common antibiotics, has specific application methods and attention in the treatment of pneumocococcal infections.
II. Characteristics of pneumococcal infections
Pneumococcus can cause a variety of diseases, most commonly pneumonia, in the form of high heat, cough, cough septosis, chest pain, and can lead to ear, nose, meningitis, etc. Its disease-causing mechanism is mainly to avoid the removal of the human immune system through the multi-sugar membrane membrane on the bacterium surface, and to cause inflammation in the local mass reproduction. The resistance of the bacteria to antibiotics such as penicillin is increasing, making the rational choice of antibiotics more critical.
III. Pharmacological properties of Archicin
Archicin is an antibiotic of the Great Ringed esters, which act by inhibiting the synthesis of bacterial proteins through a combination of 50S of bacterial nuclei. It has unique pharmacokinetic advantages, such as high tissue penetration, high concentrations in lung tissue, bronchial mucous membranes, and long half-lives, which maintain long-term antibacterial activity, usually only once a day, which is in the interest of increasing patient dependence.
IV. Use indicators for the use of Archicin in the treatment of streptococcus infections in primary health-care facilities:
When patients have typical symptoms of pneumocococcal pneumonia, such as high heat, cough rust, chest pain, etc., combined with indicators of inflammation such as white and melanoid cell rises in blood, C Reaction Protein rise, and chest X-lines or CTs show visual evidence such as actual pulmonary variability, and when considering the high risk of pneumococococcal infection, the patient may choose to be treated with aczylicin if he/she is allergic to penicillin or if the local pneumococococcus is more sensitive to the Great Pentaesteric. However, patients with severe conditions, with complications such as respiratory failure and sepsis, should be referred to a higher hospital in a timely manner to further assess the need for joint medication or for more robust antibiotic treatment programmes, such as three generations of cystactin joint achicin.
V. USE METHODOLOGY
For adult pneumocococcal infections, the common treatments for Achicillin are the first day dose of 500 mg, followed by 250 mg per day, three to five days of continuous use of drugs, generally oral delivery, to facilitate treatment and management in primary health-care facilities. For children, a daily dose of 10 mg/kg, calculated on the basis of weight, is used once a day for a period of 3-5 days. It should be noted, however, that for patients with oral or gastrointestinal ingestion disorders, intravenous drops of Achicillin may be considered, but the pace and concentration of drops should be controlled in strict accordance with the requirements of the medical instructions to avoid adverse reactions.
VI. NOTES
1. Gastrointestinal reaction: Achicillin is common for adverse effects such as gastrointestinal discomfort, vomiting, abdominal pain, diarrhoea, etc. Medical staff at the primary level should inform patients of the medication they take after eating to mitigate gastrointestinal irritation. If the adverse effects are severe and affect the food and nutritional intake of the patient, consideration should be given to adjusting the treatment programme or to taking a stoppage, with appropriate treatment for the disease, such as the use of gastric mucous membranes.
2. Drug interactions: Achicicillin interacts with certain drugs, for example, co-use with tea alkali drugs may increase blood concentration of tea alkali and increase the risk of tea alkali poisoning; co-use with geo-synthesis may lead to higher concentrations of geo-hexacinogenesis, leading to adverse effects such as cardiac disorders. When issuing the Achicillin, primary doctors should ask for details of the patient ‘ s medical history, especially for patients with heart disease, chronic obstructive pulmonary disease, who require long-term use of other drugs, avoid unreasonable combinations, adjust the dose or monitor blood concentration if necessary.
3. Drug resistance: Pneumocococcal resistance is also increasing with the widespread use of Archicin. Basic medical institutions should be regularly informed about resistance monitoring of pneumococcus in the region and, when local resistance rates are high, care should be taken to select acicin as a first-line treatment, giving priority to the use of other sensitive antibiotics, or to adjust the drug programme to the results of sensitive tests to ensure the effectiveness of treatment.
Conclusion
At the primary level, the correct use of Achicillin for the treatment of streptococcal infections requires that medical personnel accurately grasp the use of indicators, make a reasonable choice of dose and course of treatment for the patient, closely observe changes in the patient ‘ s condition and the adverse effects of the drug, while paying attention to local trends in streptococcus resistance and adapting treatment strategies in a timely manner. To improve the treatment of pneumonia streptococcal infections, to reduce the irrational use of antibiotics, to provide more safe and effective medical care for patients and to safeguard the health of the population at the grass-roots level, through the standardized and rational use of medicines.
